When Your Own Cells Become the Treatment

For decades, cancer treatment has largely focused on using medicines to destroy cancer cells or stop them from growing. But what if we could use a Patient’s own immune system to recognize and attack cancer?This is the idea behind CAR-T cell therapy, an innovative form of immunotherapy that has become an important treatment approach for some people with cancer, including multiple myeloma.

It also brings a different approach to the way treatment is delivered and supported. CAR-T is a personalized cell-based therapy that involves a complex treatment pathway alongside monitoring and supportive care. It is a highly personalized therapy that sits alongside medicines, monitoring and supportive care; requiring close collaboration between Patients and the multidisciplinary healthcare team.

What is CAR-T Therapy?

CAR-T stands for chimeric antigen receptor therapy. T cells are part of our immune system. Their normal role is to recognize and help eliminate abnormal cells, including cells infected with viruses. However, cancer cells can sometimes avoid detection by the immune system. CAR-T therapy aims to give T cells a new ability: recognizing a specific target on cancer cells and attacking them.

Unlike many conventional medicines, CAR-T therapy uses genetically modified immune cells as the therapeutic treatment. These cells are produced from the Patient’s own T cells and are designed to recognize a specific target. In simple terms, the treatment takes the Patient’s own immune cells, equips them with a new targeting system, multiplies them and puts them back into the body to find and attack cancer cells.

For Patients, this can mean a very different treatment experience from conventional cancer therapy. There is a complex journey before, during and after the infusion, and understanding what to expect can be an important part of care. Healthcare professionals, including pharmacists, play a role in helping Patients understand their medicines, supportive treatments and potential side effects throughout this journey.

Why is This Significant For Myeloma?

Multiple myeloma is a cancer of plasma cells and can become difficult to treat when it returns after several previous therapies. CAR-T therapy offers a different approach because it does not simply introduce another conventional anti-cancer drug. Instead, it uses living cells as the treatment. Clinical studies have demonstrated responses in Patients with relapsed or refractory multiple myeloma, including people who have received multiple previous treatments. The evidence and authorized use vary between individual CAR-T products and Patient populations.These findings have contributed to continued research into CAR-T therapy and its potential role in multiple myeloma.

Is CAR-T a Cure For Myeloma?

Clinical studies have reported deep responses with some CAR-T therapies in multiple myeloma, although responses vary between Patients and products. Some Patients experience prolonged responses, while others may subsequently experience disease progression. Researchers are therefore investigating how CAR-T therapy can be improved and whether it may have a role earlier in the course of myeloma. Research is also focused on understanding why some Patients experience durable responses while others subsequently experience disease progression, and on investigating ways to potentially improve the effectiveness and safety of CAR-T therapy.

What Does the Future Hold?

CAR-T therapy is still a rapidly developing field. Researchers are investigating ways to make CAR-T cells more effective, reduce side effects and overcome mechanisms that allow myeloma to return. Clinical research is also evaluating CAR-T therapy in earlier lines of treatment, including in Patients who have received fewer previous therapies. Other approaches, including bispecific antibodies, are also being developed to harness the immune system against myeloma.

The future may therefore involve increasingly personalized treatment strategies, where the biology of an individual’s myeloma may help inform research into which immune-based approaches could be appropriate.

A New Way of Thinking About Cancer Treatment

CAR-T therapy represents a different approach to treating some cancers. Instead of relying solely on medicines designed to attack cancer cells, scientists have found ways to re-engineer part of the Patient’s own immune system to recognize specific targets on cancer cells. For people living with multiple myeloma, this represents an important development in a disease where treatment options have expanded considerably over recent years. CAR-T therapy is not without risks, and it is not suitable for everyone. But as research continues, continued research may help establish how engineered immune-cell therapies can be used safely and effectively within the evolving treatment landscape for myeloma.

It also reinforces the importance of a multidisciplinary approach. As advanced therapies become part of routine cancer care, pharmacists, nurses, doctors and other healthcare professionals can contribute to helping Patients understand their treatment, manage medicines and receive appropriate supportive care throughout the treatment pathway.

The most remarkable part of CAR-T therapy may be that the treatment isn’t simply something we give to the Patient, it is something we make from the Patient’s own cells.

References

• Abecma – European Medicines Agency
• Carvykti – European Medicines Agency
• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
• Current and future use of BCMA-directed CAR T-cell therapy in MM
• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
• Treatment Decisions in Multiple Myeloma